Association between N-terminal pro-brain natriuretic peptide and adiponectin in healthy Japanese men

Clinica Chimica Acta

Volumn 460, Issue , 2016, Pages 138-141

  Nakanishi, Kaori ^a   Nishida, Makoto ^a   Yamamoto, Ryohei ^a   Koseki, Masahiro ^a   Moriyama, Toshiki ^a   Yamauchi Takihara, Keiko ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adiponectin; Intima media thickness; Metabolic disorder; Natriuretic peptides

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GLUCOSE; ADIPOQ PROTEIN, HUMAN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BIOCHEMICAL ANALYSIS; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); MALE; METABOLIC DISORDER; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; INTIMA; METABOLIC SYNDROME X; MIDDLE AGED; NORMAL HUMAN; TUNICA MEDIA;

ADIPONECTIN; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; HEALTHY VOLUNTEERS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TUNICA INTIMA; TUNICA MEDIA;

EID: 84977626643     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.06.029     Document Type: Article

References (34)

1. [1] Martinez-Rumayor, A., Richards, A.M., Burnett, J.C., Januzzi, J.L. Jr., Biology of the natriuretic peptides. Am. J. Cardiol. 101 (2008), 3–8.
2. [2] Tang, W.H., Francis, G.S., Morrow, D.A., et al. National Academy of Clinical Biochemistry Laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007), e99–109.
3. [3] Seino, Y., Ogawa, A., Yamashita, T., et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur. J. Heart Fail. 6 (2004), 295–300.
4. [4] Nishikimi, T., Maeda, N., Matsuoka, H., The role of natriuretic peptides in cardioprotection. Cardiovasc. Res. 69 (2006), 318–328.
5. [5] Sengenes, C., Berlan, M., De Glisezinski, I., Lafontan, M., Galitzky, J., Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 14 (2000), 1345–1351.
6. [6] Sugisawa, T., Kishimoto, I., Kokubo, Y., Makino, H., Miyamoto, Y., Yoshimasa, Y., Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita study. Endocr. J. 57 (2010), 727–733.
7. [7] Wang, T.J., Larson, M.G., Levy, D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004), 594–600.
8. [8] Das, S.R., Drazner, M.H., Dries, D.L., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112 (2005), 2163–2168.
9. [9] Wang, T.J., Larson, M.G., Keyes, M.J., Levy, D., Benjamin, E.J., Vasan, R.S., Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115 (2007), 1345–1353.
10. [10] Olsen, M.H., Hansen, T.W., Christensen, M.K., et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46 (2005), 660–666.
11. [11] Okamoto, Y., Kihara, S., Funahashi, T., Matsuzawa, Y., Libby, P., Adiponectin: a key adipocytokine in metabolic syndrome. Clin. Sci. (Lond.) 110 (2006), 267–278.
12. [12] Arita, Y., Kihara, S., Ouchi, N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999), 79–83.
13. [13] Cauliez, B., Guignery, J., Marinier, S., Mariau, I., Lavoinne, A., Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann. Clin. Biochem. 45 (2008), 318–319.
14. [14] Examination Committee of Criteria for ‘Obesity Disease’ in J, Japan Society for the Study of O. New criteria for ‘obesity disease’ in Japan. Circ. J. 66 (2002), 987–992.
15. [15] Matsuzawa, Y., Metabolic syndrome–definition and diagnostic criteria in Japan. J. Atheroscler. Thromb., 12, 2005, 301.
16. [16] Nishida, M., Moriyama, T., Ishii, K., et al. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin. Chim. Acta 384 (2007), 99–104.
17. [17] Morita, E., Yasue, H., Yoshimura, M., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993), 82–91.
18. [18] Omland, T., Persson, A., Ng, L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002), 2913–2918.
19. [19] Resnick, H.E., Jones, K., Ruotolo, G., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. Diabetes Care 26 (2003), 861–867.
20. [20] Dessi-Fulgheri, P., Sarzani, R., Rappelli, A., The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J. Nephrol. 11 (1998), 296–299.
21. [21] Mizuno, Y., Harada, E., Katoh, D., et al. Cardiac production of B-type natriuretic peptide is inversely related to the plasma level of free fatty acids in obese individuals - possible involvement of the insulin resistance. Endocr. J. 60 (2012), 87–95.
22. [22] Engeli, S., Birkenfeld, A.L., Badin, P.M., et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J. Clin. Invest. 122 (2012), 4675–4679.
23. [23] Miyashita, K., Itoh, H., Tsujimoto, H., et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58 (2009), 2880–2892.
24. [24] Bordicchia, M., Liu, D., Amri, E.Z., et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J. Clin. Invest. 122 (2012), 1022–1036.
25. [25] Neeland, I.J., Winders, B.R., Ayers, C.R., et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J. Am. Coll. Cardiol. 62 (2013), 752–760.
26. [26] Rankinen, T., Kim, S.Y., Perusse, L., Despres, J.P., Bouchard, C., The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int. J. Obes. Relat. Metab. Disord. 23 (1999), 801–809.
27. [27] Nakanishi, K., Nishida, M., Ohama, T., Moriyama, T., Yamauchi-Takihara, K., Smoking associates with visceral fat accumulation especially in women. Circ. J. 78 (2014), 1259–1263.
28. [28] Alberti, K.G., Zimmet, P., Shaw, J., Group, I.D.F.E.T.F.C., The metabolic syndrome–a new worldwide definition. Lancet 366 (2005), 1059–1062.
29. [29] Shibata, R., Sato, K., Pimentel, D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 11 (2005), 1096–1103.
30. [30] Kistorp, C., Faber, J., Galatius, S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005), 1756–1762.
31. [31] Ohara, T., Kim, J., Asakura, M., et al. Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens. Res. 31 (2008), 825–831.
32. [32] Verspohl, E.J., Bernemann, I.K., Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets. Peptides 17 (1996), 1023–1029.
33. [33] Lindberg, S., Jensen, J.S., Bjerre, M., et al. Cardio-adipose tissue cross-talk: relationship between adiponectin, plasma pro brain natriuretic peptide and incident heart failure. Eur. J. Heart Fail. 16 (2014), 633–638.
34. [34] Karastergiou, K., Smith, S.R., Greenberg, A.S., Fried, S.K., Sex differences in human adipose tissues - the biology of pear shape. Biol. Sex Differ., 3, 2012, 13.